Discovery and early characterization
In 1975, researchers at the Karolinska Institute in Stockholm were running what should have been routine control experiments. Under the prevailing model, immune cells from mice that had never been exposed to a tumor were expected to leave tumor cells alone, because killing was thought to require prior sensitization. Instead, the unsensitized cells killed on contact. Rolf Kiessling and colleagues named the unexplained population "natural" killer cells, for their ability to kill naturally, without priming.[1]
That incidental observation founded an entire branch of immunology. NK cells proved to be a distinct lymphocyte lineage, neither T cell nor B cell, belonging to the innate immune system: the constitutive arm that responds within hours rather than the days an antibody response requires. A fiftieth-anniversary review published in 2026 traces the field from that initial observation to today's engineered NK therapies: a cell population dismissed for years as an experimental artifact is now the platform for some of the most closely watched clinical trials in medicine.[2]
The central conceptual advance came in the 1980s with the "missing self" hypothesis. Most immune recognition operates by detecting a foreign element that is present. NK cells largely operate in the opposite direction: they check each cell they contact for the surface molecule MHC class I, which nearly all healthy cells display. Virus-infected cells and tumor cells frequently downregulate MHC class I to evade T cells, and that absence is precisely what NK cells detect. A cell that fails to display MHC class I is recognized and killed. Ljunggren and Kärre set out the argument and the supporting in vivo evidence in the review that gave the hypothesis its name.[8]
- In one sentence
- A natural killer cell is an innate immune lymphocyte that patrols the body continuously and destroys cells that are infected, malignant, or stressed, recognizing them not by prior sensitization but by missing or altered surface signals.
Effector functions and surveillance targets
An adult human carries on the order of billions of NK cells, roughly five to fifteen percent of circulating lymphocytes, turning over constantly. Their primary function is surveillance. Each NK cell integrates signals from a panel of activating and inhibitory receptors as it contacts neighboring cells; when the balance tips toward activation, it kills within minutes, releasing perforin, a protein that forms pores in the target's membrane, and granzymes, enzymes that enter through those pores and trigger the target's programmed cell death.[3]
Three categories of target are most significant. The first is virus-infected cells: individuals with rare congenital NK deficiencies suffer severe, recurrent herpesvirus infections, which is among the clearest evidence of the protection these cells normally provide.[9] The second is malignant cells, the subject of the original 1975 observation. Tumors arise continuously at the single-cell level and are, in the standard model of immunosurveillance, mostly eliminated before they become clinically detectable; NK cells contribute to that early elimination. The third category has received less attention but is increasingly relevant to aging biology: senescent cells.
NK cells also have functions beyond direct cytotoxicity. They secrete interferon-gamma and other cytokines that recruit and instruct the rest of the immune system, shaping the slower adaptive response. This signaling role is one reason their dysfunction has such broad consequences. It is also one point of genuine contact with the mesenchymal stromal cells covered elsewhere in this journal: MSCs, in inflamed tissue, are known to modulate NK cell activity as part of their general immunomodulatory program, one of several ways the two cell types interact even though they perform very different work.[3]
Age-related decline in NK cell function
This section concerns the aspect of NK biology most directly relevant to longevity medicine. NK cell numbers remain relatively stable with age, and in many studies they even rise. NK cell function does not follow the same pattern. Aging shifts the population toward a mature subset with reduced proliferative capacity, and the killing efficiency of individual cells declines: reduced cytotoxicity per cell, slower target binding, and blunted cytokine secretion. A detailed review by Hazeldine and Lord links this measurable decline in NK function to the documented vulnerabilities of older adults: higher rates and severity of viral infection, poorer vaccine responses, and rising cancer incidence.[4] A more recent review of NK cell immunosenescence describes the same dissociation, reporting reduced cytokine secretion and reduced per-cell cytotoxicity alongside, and despite, an increase in NK cell numbers with age.[10]
The age-related deficit is not a loss of the NK cells themselves. The cells remain present in circulation but kill less efficiently when they encounter a target.
The senescent-cell connection makes this decline bidirectional in its consequences. Senescent cells (aged, damaged cells that stop dividing but do not die, and that secrete inflammatory signals which degrade surrounding tissue) display stress ligands that NK cells recognize through their activating receptor NKG2D, marking them for removal.[5] Experimental work shows that when this NKG2D-mediated surveillance is impaired, senescent cells accumulate in tissue. In one of the founding experiments for this idea, NK cells were shown to clear senescent activated stellate cells from injured mouse liver, and blunting that clearance left more senescent cells behind and worsened fibrosis.[11] Declining NK function therefore does not merely weaken defense against infection and malignancy; it plausibly accelerates the accumulation of the senescent cells that drive chronic, low-grade inflammation, the "inflammaging" explained in depth in this journal's cellular-aging article. An aging immune system and an aging body are not two separate problems.
Therapeutic development
Two lines of work account for the current interest. The first is CAR-NK: applying the chimeric antigen receptor technology behind CAR-T cancer therapy to NK cells instead. In the landmark trial at MD Anderson, cord-blood-derived CAR-NK cells produced responses in 73 percent of patients with relapsed lymphoid cancers, and none of the patients developed cytokine release syndrome or neurotoxicity, the two most serious complications of CAR-T.[6] In this trial, NK cells appear to have retained much of the therapeutic activity while producing substantially less toxicity. The larger follow-up from the same group, a phase 1/2 trial of 37 patients published in 2024, reported a day 30 overall response rate of 48.6 percent, again with no notable cytokine release syndrome, neurotoxicity, or graft-versus-host disease.[12] The lower response rate in the larger cohort is the more informative figure, and it is a reminder that early results from very small groups of patients usually moderate as the numbers grow.
The second is the Stanford tissue-resident NK work published in 2026. To understand why it drew attention, it helps to state the problem it addresses. NK cell therapy has produced its clearest results in blood cancers, where the malignant cells circulate and the infused NK cells meet them directly. Solid tumors are a different proposition: infused NK cells remain largely in the bloodstream, enter tumor tissue in small numbers, and lose function in the suppressive environment they encounter there. Poor infiltration, rather than poor killing ability, has been the principal barrier.[7]
John Sunwoo's group at Stanford approached this by changing what kind of NK cell is infused rather than what it targets. Tissue-resident NK cells are a naturally occurring population that takes up residence in tissue instead of circulating, and they carry a distinct surface signature, CD39, CD49a, and CD103, that the researchers used to identify them. The group found that exposure to transforming growth factor beta (TGF-β), delivered through direct contact with short-lived epithelial tumor cells, converts conventional donor NK cells into this tissue-resident form.[7]
The conditioning is narrowly dose-dependent, which is the mechanistically interesting part. TGF-β is ordinarily understood as an immunosuppressive signal that tumors use to disable immune cells, and at high exposure it does exactly that: the cells become tissue-resident but dysfunctional. At a lower, transient exposure, the same signal produces tissue-resident cells that retain strong cytotoxic activity. The therapeutic window depends on delivering enough signal to convert the cells and not enough to disable them. In mouse models, adoptive transfer of the converted cells infiltrated tumors and reduced tumor burden in head and neck squamous cell carcinoma and melanoma, with the effect strongest when combined with antibody therapy.[7]
The limitations deserve equal weight. This is a mouse study. It demonstrates that the conversion is achievable and that the converted cells behave as intended in animal models, which is a meaningful proof of concept for a barrier the field has not solved, but it is not evidence of benefit in humans. No clinical trial of this approach has reported results, and the distance between a mouse tumor model and a treated patient is where most promising cancer immunotherapies have historically failed.
The necessary caveat comes from the study's own senior author, who called the work proof of concept and warned against extrapolating from mice to humans. That framing applies to the field as a whole: the biology is of genuine scientific interest, one human trial in blood cancers has published striking results, and everything in solid tumors remains preclinical or in early trials. Adjacent cell-therapy platforms sit at a comparable stage of development, and one of them, the Muse cell, is described in this library's Muse cell article.
Current clinical status and implications
The gap between this science and the commercial marketplace warrants attention. Engineered NK therapies (CAR-NK and tissue-resident NK) exist inside registered clinical trials at academic centers, for cancer. They are not something any clinic, in any country, can legitimately sell you today, and a provider advertising NK cell infusions as a cancer treatment outside a trial is displaying exactly the warning signs described in our article on safety and vetting. TrueCell does not treat cancer, and this article should not be read as an offer to. Patients researching cell therapy in México can review the protocols actually available here, which address orthopedic, autoimmune, and longevity indications rather than oncology.
There are two reasons an article on NK cells belongs in a regenerative-medicine journal. First, the aging biology is directly relevant: NK function is a measurable component of immune aging, connected through senescent-cell surveillance to the inflammaging that longevity protocols target.[4][5] Understanding it helps a patient interpret both their own immune panel and the field's marketing more accurately. Second, NK cells interact continuously with the mesenchymal stromal cells that regenerative protocols actually use: MSCs modulate NK activity as part of the same immunomodulatory program that reduces inflammation in tissue, described in the MSC explainer. The immune system operates as one interconnected network, and understanding one participant informs understanding of the others.
The practical conclusions parallel those found elsewhere in this journal. The basic behavioral factors that influence NK function (sleep, exercise, and metabolic health) have real supporting literature and cost nothing. The frontier therapies warrant continued attention and honest description. A clinic that blurs the distinction between the two categories reveals something important about its standards.
Common questions
What do natural killer cells actually do?
NK cells are innate immune lymphocytes that inspect the cells they touch and kill the ones that look wrong, without needing prior exposure to that threat. Their usual targets are virus-infected cells, early malignant cells, and senescent cells, which they identify largely by missing or altered surface signals rather than by a specific antigen.[3][8] They also release interferon-gamma and other cytokines that direct the slower adaptive immune response.
Can declining NK cell function be restored?
Honest answer: not reliably, and not by any product currently sold to consumers. The decline is well documented, and the basic behavioral factors associated with better NK function in the literature are sleep, regular exercise, and metabolic health.[4][10] Whether any intervention durably restores age-related NK function in humans, and whether doing so would change clinical outcomes, has not been established.
Is NK cell therapy available to patients today?
Engineered NK cell therapies exist inside registered clinical trials at academic centers, mainly for blood cancers, and the published human data come from small early-phase studies.[6][12] They are not an approved product that a clinic in any country can legitimately sell outside a trial. TrueCell does not treat cancer and does not offer NK cell therapy; patients considering cell therapy in México should ask any provider which specific trial or regulatory pathway a proposed NK protocol falls under.